Stearoylcarnitine

Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2^{[1][2][3][4][5]}. In Vitro:Stearoylcarnitine (100 μM, 2 h) impairs mitochondrial energy metabolism in MIN6 cells^[1].
Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency via excessive β-oxidation and depletion of tricarboxylic acid (TCA) cycle and oxidative phosphorylation metabolites in type 2 diabetes (T2D) mouse pancreatic tissues^[1].
Stearoylcarnitine (1 μM, 25 min) significantly abolishes the stimulatory effect of triterpene derivative on ⁴⁵Ca²⁺ influx in pancreatic islets of male Wistar rats^[5].
In Vivo:Stearoylcarnitine increases in the cortex, striatum/thalamus, and cerebellum in CD1 mouse pups (postnatal day 9) with hypoxic-ischemic brain injury (HIBI) induced by carotid artery ligation^[2].
Stearoylcarnitine (500 μM, 0-40 min) shows inhibitory towards lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma, but not in human plasma^[3].
Stearoylcarnitine is characterized as one of potential biomarkers involved in the pathogenesis of Parkinson’s disease (PD) ^[4].